(19)
(11) EP 1 453 956 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.02.2010 Bulletin 2010/06

(45) Mention of the grant of the patent:
28.10.2009 Bulletin 2009/44

(21) Application number: 02792957.9

(22) Date of filing: 10.12.2002
(51) International Patent Classification (IPC): 
C12N 7/02(2006.01)
 C12N 5/00(2006.01)
(86) International application number:
PCT/EP2002/014011
(87) International publication number:
WO 2003/054174 (03.07.2003 Gazette 2003/27)

(54)

METHOD FOR LARGE SCALE PRODUCTION OF VIRUS ANTIGEN

VERFAHREN ZUR PRODUKTION VON VIRALEN ANTIGENEN IM GROSSMASSSTAB

PROCEDE AMELIORE DE PRODUCTION EN SERIE D'ANTIGENE VIRAL

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR
Designated Extension States:
AL LT LV MK RO

(30) Priority: 10.12.2001 US 6881

(43) Date of publication of application:
08.09.2004 Bulletin 2004/37

(60) Divisional application:
07021348.3 / 1894998

(73) Proprietor: Baxter Healthcare S.A.
8152 Glattpark (Opfikon) (CH)

(72) Inventors:
  • REITER, Manfred
    A-1150 Vienna (AT)
  • MUNDT, Wolfgang
    A-1080 Vienna (AT)

(74) Representative: Müller-Boré & Partner Patentanwälte 
Grafinger Strasse 2
81671 München
81671 München (DE)


(56) References cited: : 
WO-A-91/09935
   
  • KISTNER O ET AL: "[Development of a novel influenza vaccine derived from a continuous cell line]" ALTEX: ALTERNATIVEN ZU TIEREXPERIMENTEN. GERMANY 2001, vol. 18, no. 1, 2001, pages 50-54, XP001146190 ISSN: 0946-7785
  • KISTNER O ET AL: "NOVEL MAMMALIAN CELL (VERO) DERIVED INFLUEZY VIRUS VACCINE: DEVELOPMENT, CHARACTERIZATION AND INDUSTRIAL SCALE PRODUCTION" WIENER KLINISCHE WOCHENSCHRIFT, NEW YORK, NY, US, vol. 111, no. 5, 1999, pages 207-214, XP000909353 ISSN: 0043-5325
  • BARRETT N ET AL: "LARGE-SCALE PRODUCTION AND PURIFICATION OF A VACCINIA RECOMBINANT-DERIVED HIV-1 GP160 AND ANALYSIS OF ITS IMMUNOGENICITY" AIDS RESEARCH AND HUMAN RETROVIRUSES, NEW YORK, NY, US, vol. 5, no. 2, April 1989 (1989-04), pages 159-172, XP001064669 ISSN: 0889-2229
  • PERCHESON P B ET AL: "A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line." DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, vol. 98, 1999, pages 127-132, XP009008177 Meeting of the National Institute for Biological Standards and Control;Herts, England, UK; September 26-27, 1997, vaccines prepared in cell culture. 1999 S. Karger AG; S. Karger AG P.O. Box, Allschwilerstrasse 10, CH-4009 Basel, Switzerland; New York, New York, USA ISBN: 3-8055-6896-7
  • SHARKEY C MATTHEW ET AL: "Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production." JOURNAL OF VIROLOGY, vol. 75, no. 6, March 2001 (2001-03), pages 2653-2659, XP002235506 ISSN: 0022-538X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).